Umifenovir (Arbidol) Efficacy in Experimental Mixed Viral and Bacterial Pneumonia of Mice

Pneumonia often occurs as a secondary infection after influenza and accounts for a large proportion of the morbidity and mortality associated with seasonal and pandemic influenza outbreaks. The efficacy of umifenovir (Arbidol) was investigated on a murine model of S.aureus pneumonia following A/Cali...

Full description

Saved in:
Bibliographic Details
Published inАнтибиотики и Химиотерапия Vol. 59; no. 9-10; pp. 17 - 24
Main Authors I. A. Leneva, I. N. Falynskova, E. I. Leonova, I. T. Fedyakina, N. R. Makhmudova, E. A. Osipova, L. N. Lepekha, N. A. Mikhailova, V. V. Zverev
Format Journal Article
LanguageRussian
Published LLC "Publishing House OKI" 01.05.2020
Subjects
bacterial pneumonia after influenza
influenza
s.aureus
umifenovir (arbidol)
Online AccessGet full text

Cover

More Information
Summary:Pneumonia often occurs as a secondary infection after influenza and accounts for a large proportion of the morbidity and mortality associated with seasonal and pandemic influenza outbreaks. The efficacy of umifenovir (Arbidol) was investigated on a murine model of S.aureus pneumonia following A/California/04/2009 (H1N1) influenza virus infection . Oral treatment with umifenovir (40 and 60 mg/kg/day ) in all the contamination schemes increased the survival rate in the mice from 0% to 90% and lowered the animal weight loss. The umifenovir treatment also decreased the virus titer by >2 logs and the viable bacteria counts in the lungs of the mice. The lungs of the mice treated with umifenovir had less severe histopathologic lesions compared to the control group.
ISSN:0235-2990